enVVeno Medical Corporation provided an update on enrollment for its ongoing SAVVE (Surgical Anti-reflux Venous Valve Endoprosthesis) U.S. pivotal study for the VenoValve and announced two upcoming investor events. The SAVVE pivotal study is a prospective, non-blinded, single arm, multi-center study of 75 CVI patients. To date, the Company has enrolled 57 patients in the study and expects enrollment to be completed before the end of 2023.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.005 USD | +0.10% | +0.70% | -2.63% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.63% | 66.65M | |
+33.15% | 49.46B | |
+1.94% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+12.21% | 26.61B | |
-23.07% | 18.64B | |
+8.38% | 13.16B | |
+30.32% | 12.55B | |
+24.17% | 12.1B |
- Stock Market
- Equities
- NVNO Stock
- News enVVeno Medical Corporation
- Envveno Medical Corporation Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study